IAIM
IBRX icon

International Assets Investment Management’s ImmunityBio IBRX Stock Holding History

International Assets Investment Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$920 Hold
100
– – ﹤0.01% 2211
2026
Q1 		$714 Buy
+100
New +$685 ﹤0.01% 2099

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

International Assets Investment Management's IBRX Position: Q2 2026 in Review

International Assets Investment Management held its ImmunityBio (IBRX) position steady in Q2 2026 at 100 shares worth $920. The position accounts for ﹤0.01% of the portfolio, ranked #2211.

International Assets Investment Management first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 273 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • International Assets Investment Management held 100 shares of ImmunityBio worth $920 as of Q2 2026.
  • International Assets Investment Management left its ImmunityBio share count unchanged in Q2 2026.
  • ImmunityBio made up ﹤0.01% of International Assets Investment Management's portfolio in Q2 2026, its #2211 holding.
  • International Assets Investment Management first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
  • 273 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on International Assets Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.